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 G protein-coupled receptors and tyrosine
kinase receptors signal through the
phosphoinositide 3-kinase/Akt/mTOR
pathway to induce cell proliferation,
survival, and growth. mTOR is a kinase
present in 2 functionally distinct
complexes, mTORC1 and mTORC2.
 Functional disruption of mTORC1 by
knockout of Raptor (regulatory
associated protein of mammalian target
of rapamycin) in smooth muscle cells
ameliorated the development of
experimental PH.
 Functional disruption of mTORC2 by
knockout of Rictor (rapamycin insensitive
companion of mammalian target of
rapamycin) caused spontaneous PH by
up-regulating platelet-derived growth
factor receptors.
 Use of mTOR inhibitors (e.g., rapamycin)
to treat PH should be accompanied by
inhibitors of platelet-derived growth
factor receptors (e.g., imatinib).https://doi.org/10.1016/j.jacbts.2018.08.009
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AB BAND ACRONYM S
EC = endothelial cell
FOXO3a = Forkhead box O3a
GPCR = G protein-coupled
receptor
HPH = hypoxia-induced
pulmonary hypertension
mTORC1 = mammalian target
of rapamycin complex 1
mTORC2 = mammalian target
of rapamycin complex 2
PA = pulmonary artery
PAEC = pulmonary arterial
endothelial cell
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MaConcentric lung vascular wall thickening due to enhanced proliferation of pulmonary arterial smooth muscle
cells is an important pathological cause for the elevated pulmonary vascular resistance reported in patients with
pulmonary arterial hypertension. We identified a differential role of mammalian target of rapamycin (mTOR)
complex 1 and complex 2, two functionally distinct mTOR complexes, in the development of pulmonary hy-
pertension (PH). Inhibition of mTOR complex 1 attenuated the development of PH; however, inhibition of mTOR
complex 2 caused spontaneous PH, potentially due to up-regulation of platelet-derived growth factor receptors
in pulmonary arterial smooth muscle cells, and compromised the therapeutic effect of the mTOR inhibitors on
PH. In addition, we describe a promising therapeutic strategy using combination treatment with the mTOR
inhibitors and the platelet-derived growth factor receptor inhibitors on PH and right ventricular hypertrophy.
The data from this study provide an important mechanism-based perspective for developing novel therapies for
patients with pulmonary arterial hypertension and right heart failure. (J Am Coll Cardiol Basic Trans Science
2018;3:744–62) © 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology
Foundation. This is an open access article under theCCBY license (http://creativecommons.org/licenses/by/4.0/).
= pulmonary arterial
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T = phosphorylated AKTPAH
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pAKSEE PAGE 763
PASMC = pulmonary arterial
smooth muscle cell
PDGF = platelet-derived
growth factor
PDGFR = platelet-derived
growth factor receptor
PH = pulmonary hypertension
PI3K = phosphoinositide
3-kinase
PTEN = phosphatase and
tensin homolog
PVR = pulmonary vascular
resistance
Raptor = regulatory associated
protein of mammalian target of
rapamycin
Rictor = rapamycin insensitive
companion of mammalian
target of rapamycin
RVH = right ventricular
hypertrophy
RVSP = right ventricular
systolic pressure
SM = smooth muscle
TKR = tyrosine kinase receptor
WT = wild-typeI diopathic pulmonary arterial hypertension(PAH) is a progressive and fatal disease in whichincreased pulmonary vascular resistance (PVR)
leads to right ventricular dysfunction and failure,
and to premature death (1). Sustained pulmonary
vasoconstriction and excessive pulmonary vascular
remodeling, characterized by concentric pulmonary
arterial wall thickening and occlusive intimal and
plexiform lesions in the distal pulmonary artery
(PA), are the 2 major causes for elevated PVR in pa-
tients with idiopathic and associated PAH and in an-
imals with experimental pulmonary hypertension
(PH) (2–5). The proximal and distal PA wall is histo-
logically composed of 3 layers of structure separated
by elastic lamina: the adventitia formed mainly by
fibroblasts and extracellular matrix, the media
formed mainly by smooth muscle cells, and the
thin intimal mainly formed by endothelial cells
(ECs) (6). Although pulmonary arterial smooth mus-
cle cell (PASMC) contraction is the primary cause
for vasoconstriction, increased PASMC proliferation
and migration are implicated in the development
and progression of concentric PA wall thickening
and arteriole and precapillary muscularization (7,8).
Multiple mechanisms and numerous intracellular
signaling cascades are involved in stimulatingod Institute of the National Institutes of Health (HL135807, HL142214, a
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develop pulmonary vascular remodeling
(2,9–15).The phosphoinositide 3-kinase (PI3K)/
AKT/mammalian target of rapamycin (mTOR)
pathway, one of the critical signaling cas-
cades involved in cell proliferation (16), can
be activated by various growth factors and
mitogenic cytokines (17–19). We and other
investigators have shown that the PI3K/Akt1/
mTOR signaling pathway plays an important
role in the regulation of PASMC proliferation
and the development of PH (16,20). Activa-
tion of the PI3K/AKT/mTOR pathway in
PASMCs is through various stimuli such as
platelet-derived growth factor (PDGF),
endothelin-1 (21,22), stress, and hypoxia (23).
Global knock-out (KO) of the Akt1 gene
(Akt1/), but not the Akt2 gene (Akt2/),
significantly inhibited the development of
experimental PH in mice (16), whereas over-
expression of the phosphatase and tensin
homolog (PTEN), a negative regulator of the PI3K/
AKT/mTOR pathway (24,25), exerted a similarnd HL125208). Dr. Garcia is the founder, CEO, and
reported that they have no relationships relevant to
and animal welfare regulations of the authors’ in-
nsent where appropriate. For more information, visit
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genic mice (16).
The downstream signaling protein, mTOR, in the
PI3K/AKT/mTOR pathway is a serine/threonine kinase
that belongs to the PI3K-related kinase family (26). We
previously reported that conditional and inducible KO
of mTOR in smooth muscle cells almost completely
inhibited the development of PH in mice (16). These
data provide compelling evidence that the PI3K/AKT1/
mTOR signaling pathway in PASMC plays an important
role in the development of PH. Specifically targeting
signaling proteins and kinases in the PI3K/AKT1/
mTOR cascade may help develop novel therapeutic
approaches for idiopathic and associated PAH, as well
as PH associated with lung diseases and hypoxia.
mTOR is a downstream signaling protein and a
serine/threonine kinase of AKT1. mTOR is also a major
kinase present in 2 functionally distinct complexes:
the mTOR complex 1 (mTORC1) and the mTOR com-
plex 2 (mTORC2) (27). mTORC1 is composed of mTOR,
Raptor (regulatory associated protein of mammalian
target of rapamycin), Pras40, GbL, and DEPTOR, and is
inhibited by rapamycin and KU 0063794; mTORC2 is
composed of mTOR, Rictor (rapamycin insensitive
companion of mammalian target of rapamycin), GbL,
Sin1, PRR5/Protor-1, and DEPTOR (26), and is inhibited
by KU 0063794 (28). The individual protein complexes
of mTORC have different upstream and downstream
regulators (26). mTORC1 is a master growth regulator
that promotes cell proliferation in response to growth
factors, extracellular nutrients, and amino acids;
mTORC2 promotes cell survival by activating AKT,
regulates cytoskeletal dynamics by activating protein
kinase C alpha, and controls ion transport and cell
growth via serum/glucocorticoid-inducible kinase 1
phosphorylation. Global deletion of mTOR would
disrupt the function of both mTORC1 and mTORC2.
A relatively new topic of research in the field of
pulmonary vascular disease is to understand the
individual or differential roles of mTORC1 and
mTORC2 in PASMC proliferation and the development
of PAH/PH. The mTORC1 and mTORC2 also differ in
their sensitivity to rapamycin; that is, short-term
treatment with rapamycin inhibits mTORC1, but
long-term treatment with rapamycin can inhibit
both mTORC1 and mTORC2 (29).
Significant research is being conducted in under-
standing the role of mTOR, as a common component
in both mTORC1 and mTORC2, in the development of
hypoxia-induced PH by promoting PASMC prolifera-
tion (30,31). The aim of the present study was to
examine whether mTORC1 and mTORC2 potentially
play a differential role in the development of PH. We
generated the following: 1) smooth muscle (SM)-specific Raptor KO mice (RaptorSM/) to inhibit
mTORC1 function in PASMCs; and 2) SM-specific
Rictor KO mice (RictorSM/) to inhibit mTORC2
function in PASMCs. We then conducted a series of
experiments in wild-type (WT) RaptorSM/ and
RictorSM/ mice using combined techniques of
in vitro cell and molecular biology, and in vivo he-
modynamic measurement in intact mice, to define
whether mTORC1 and mTORC2 are differentially
involved in the development of PH and whether in-
hibition of mTORC1 and mTORC2 exerts the same
therapeutic effect on experimental PH.
METHODS
A more detailed Methods and Materials section for
this study is given in the Supplemental Material. The
animal experimental procedures were approved by
the Institutional Animal Care and Use Committee of
The University of Arizona (Tucson, Arizona). All ani-
mals were bred and housed in the University of Ari-
zona Animal Research Center. Standardized protocols
were followed for conducting the experiments using
rodent model.
RESULTS
We first conducted in vivo experiments using WT and
various KO mice to examine whether SM-specific KO
of mTOR (mTORSM/), Raptor (RaptorSM/), and
Rictor (RictorSM/) exerted protective effects on
experimental PH. In vitro Western blot experiments
were then conducted by using PA isolated from WT
and KO mice to examine whether functional disrup-
tion of mTORC1 in mTORSM/ and RaptorSM/ mice
or mTORC2 in mTORSM/ and RictorSM/ mice af-
fects protein expression of platelet-derived growth
factor receptor (PDGFR) a and PDGFRb in PASMCs.
Finally, we examined and compared the level of
phosphorylated AKT (pAKT), a downstream signaling
protein of mTORC2 and an upstream signaling protein
of mTORC1, in PA isolated from WT and KO mice and
in PASMCs isolated from normal subjects and patients
with idiopathic PAH.
CONDITIONAL AND INDUCIBLE KO OF mTOR IN
PASMCs SIGNIFICANTLY INHIBITS THE DEVELOPMENT OF
EXPERIMENTAL PH. To examine the role of mTOR
(which is required for the function of both mTORC1
and mTORC2) in PASMC proliferation and the devel-
opment of hypoxia-induced pulmonary hypertension
(HPH), we first generated the SM-specific mTOR con-
ditional and inducible KO mice (mTORSM/)
(Figure 1Aa) through crossing the floxed mTOR mice
with a transgenic mouse line expressing a fusion
FIGURE 1 mTOR (mTORC1/mTORC2) in Smooth Muscle Cells and Pulmonary Hypertension
Smooth muscle (SM)-specific conditional and inducible knock-out (KO) of mTOR attenuates hypoxia-induced pulmonary hypertension in mTORSM/ mice. (A) Sche-
matic strategy for the generation of mTORSM/ mice (a) and the timeline indicating the time for injection of tamoxifen (Tam) (to induce mTOR KO), hypoxic exposure
(for inducing pulmonary hypertension) and experimental measurements (b). (B) Representative immunofluorescence images showing cell nuclei (40,60-diamidino-2-
phenylindole [DAPI]; blue), smooth muscle cells (smooth muscle actin [SMA]; red), and mammalian target of rapamycin (mTOR; green) in the cross-section of small
pulmonary artery (PA) in lung tissues from wild-type (WT) (mTOR-Oil) and mTORSM/ (mTOR-Tam) mice (a). Summarized data (mean  SE; n ¼ 5 in each group) for
DAPI, SMA, and mTOR fluorescence intensity are shown in panels b. It is noted that the mTOR (green) expression is almost abolished in the SMA-positive PA wall in
mTOR-Tam mice but preserved in the mTOR-Oil mice. Student’s t-test (DAPI and SMA level) and Welch’s t-test (mTOR level), **p < 0.01 and ***p < 0.001 versus
mTOR-Oil. (C) Representative record of right ventricular pressure (RVP) in WT and mTORSM/ mice exposed to normoxia (room air, 21% oxygen) and hypoxia (10%
oxygen for 3 weeks) (a). Summarized data (mean  SE) showing the peak value of right ventricular systolic pressure (RVSP) (b) (Kruskal-Wallis test, p < 0.001) and
the Fulton index (the ratio of weight of the right ventricle divided by weight of the left ventricle plus the septum [RV/(LV þ S)]) (c) (Kruskal-Wallis test, p ¼ 0.005) in
WT and mTORSM/ mice exposed to normoxia and hypoxia. Dunn test, *p < 0.05, ***p < 0.001 versus Normoxia-WT; ##p < 0.01 versus Hypoxia-WT. (D) Repre-
sentative hematoxylin and eosin images (a) of the cross-section of small PA and summarized data (mean  SE) (b) showing the PA wall thickness in WT and
mTORSM/ mice under normoxic and hypoxic conditions. Kruskal-Wallis test, p < 0.001; Dunn test, **p < 0.01, *p < 0.05 versus Normoxia-WT, ##p < 0.01 versus
Hypoxia-WT. (E) Summarized data (mean SE) showing the number of red blood cells (RBC) (Kruskal-Wallis test, p¼ 0.04), hemoglobin concentration (HGB) (Kruskal-
Wallis test, p¼ 0.01), and hematocrit percentage (HCT) (Kruskal-Wallis test, p¼ 0.01) in WT andmTORSM/mice exposed to normoxia and hypoxia. Analysis of variance,
**p < 0.01, *p < 0.05 versus Normoxia-WT; #p < 0.05 versus Hypoxia-WT. The numbers of experiments (n) for each group are indicated in each bar.
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748protein of the Cre recombinase with the modified
estrogen receptor binding domain (CreERT2) under
the control of the SM myosin heavy chain promoter.
To induce the KO of mTOR, we treated the Creþm-
TORF/F mice with tamoxifen 5 times consecutively
and waited for 1 to 2 weeks prior to exposing the mice
to hypoxia (for 3 weeks) (Figure 1Ab). The control mice
were treated with vehicle (Oil). Immunohistochem-
ical staining of the PA in lung tissues showed that
mTOR was expressed in all cell types, including
PASMCs, in CreþmTORF/F mice treated with the
vehicle (Oil), whereas the mTOR expression was
hardly detected in PASMCs or in PA in mTORSM/
mice after treatment with tamoxifen (Figure 1B).
Deletion of mTOR would disrupt the function of
both mTORC1 and mTORC2 (32). In this study, we
repeated the experiments (Figure 1C) showing that SM-
specific deletion of mTOR significantly inhibited the
development of HPH. Chronic hypoxia-mediated in-
creases in right ventricular systolic pressure (RVSP)
(Figures 1Ca and 1Cb) in Creþ/mTORF/F mice treated
with vehicle Oil (WT) was significantly attenuated
compared with Creþ/mTORF/F mice treated with
tamoxifen (mTORSM/). The reduced RVSP was asso-
ciated with the down-regulation of mTOR protein
expression level in PASMCs (Figure 1Bb).
In addition to the change in RVSP, the hypoxia-
induced pulmonary vascular wall thickening, deter-
mined by the PA wall thickness, was also significantly
inhibited in mTORSM/mice compared with WT mice
(Figure 1D). Hypoxia also resulted in polycythemia,
indicated by the increased number of red blood cells,
hemoglobin concentration (grams per deciliter) and
hematocrit percentage (Figure 1E). It is noted that the
hypoxia-induced polycythemia effect on red blood cell
count and hemoglobin was also significantly inhibited
in mTORSM/ mice compared with WT mice. These
data, consistent with our previous study (16), indicate
that SM-specific deletion of mTOR, a serine/threonine
kinase that is pivotal for the function of both mTORC1
and mTORC2, significantly inhibits the development
of pulmonary arterial remodeling and HPH. The next
set of experiments was designed to investigate
whether mTORC1 and mTORC2 complexes are differ-
entially involved in HPH.
CONDITIONAL AND INDUCIBLE DELETION OF
RAPTOR IN PASMCs SIGNIFICANTLY INHIBITS THE
DEVELOPMENT OF EXPERIMENTAL PH. To examine
the role of Raptor, which is responsible for the func-
tion of mTORC1, in PASMC proliferation, pulmonary
vascular remodeling, and the development of PH, we
generated SM-specific conditional and inducible
Raptor KO mice (Figure 2Aa) using the same strategyas we used for generating mTORSM/. Raptor defi-
ciency in tamoxifen-treated CreþRaptorF/F mice was
verified by Western blot analysis of pulmonary arte-
rial vascular wall lysates from the respective mice
(Figure 2Ab). To induce the KO of Raptor, we treated
the CreþRaptorF/F mice with tamoxifen and waited for
1 to 2 weeks prior to exposure of the mice to hypoxia
(for 3 weeks) for experiments (Figure 2Ac).
Raptor is expressed in PASMCs or PA in control
mice (Figure 2Ba), whereas Raptor expression is
significantly decreased in RaptorSM/ mice
(Figure 2Bb, right panel). To examine the role of
Raptor or mTORC1 in the development of experi-
mental PH, we measured and compared the pulmo-
nary hemodynamic variables (e.g., RVSP), right
ventricular hypertrophy (RVH) (e.g., Fulton index)
and pulmonary vascular remodeling (e.g., PA wall
thickness) in RaptorSM/ and WT mice before and
after exposure to hypoxia for 3 weeks. No significant
difference in the basal pulmonary hemodynamic
variables (e.g., RVSP) was observed between WT and
RaptorSM/ mice under normoxic conditions
(Figures 2Ca and 2Cb). Exposure of WT mice to nor-
mobaric hypoxia (10% O2) for 3 weeks resulted in
significant increases in RVSP (from 23.5  0.05 mm Hg
to 39.8  0.12 mm Hg; p < 0.001) (Figures 2Ca and 2Cb)
and in the Fulton index (the ratio of weight of the
right ventricle divided by weight of the left ventricle
plus the septum [RV/(LV þ S)] (from 0.28  0.01 to
0.42  0.07) (Figure 2Cc). In RaptorSM/ mice, the
hypoxia-mediated increases in RVSP were slightly
attenuated, but not statistically significant, and
the RV/(LV þ S) ratio was significantly attenuated
compared with that in WT mice. These data indicate
that SM-specific deletion of Raptor or SM-specific
disruption of mTORC1 kinase activity exerts partial
protective effects on experimental PH.
CONDITIONAL AND INDUCIBLE DELETION OF
RICTOR INCREASES BASAL RVSP AND NEGLIGIBLY
AFFECTS THE DEVELOPMENT OF HPH. It has been
reported that mTORC2 has different physiological
functions compared with mTORC1 (20,33,34), and
the functions and regulatory mechanisms of
mTORC2 are less characterized and studied, espe-
cially in smooth muscle cells or PASMCs. To un-
derstand the potential role of Rictor or mTORC2 in
the development of PH, we generated the SM-
specific conditional and inducible Rictor KO mice
(RictorSM/) (Figure 3Aa). Rictor deficiency in
RictorSM/ mice was verified by Western blot
analysis of pulmonary arterial vascular wall lysates
from the respective mice (Figure 3Ab). To induce the
KO of Rictor, we treated the CreþRictorF/F mice with
FIGURE 2 Raptor (mTORC1) in Smooth Muscle Cells and Pulmonary Hypertension
SM-specific conditional and inducible KO of Raptor attenuates hypoxia-induced pulmonary hypertension in RaptorSM/ mice. (A) Schematic strategy for the generation
of RaptorSM–/– mice (a); Western blot analysis of Raptor (regulatory associated protein of mammalian target of rapamycin) in isolated PA fromWT and RaptorSM/mice
(b); and the timeline indicating the time for Tam injection (to induce Raptor KO), hypoxic exposure (to induce PH), and experimental measurements (c). (B) Repre-
sentative immunofluorescence images showing cell nuclei (DAPI; blue), smooth muscle cells (SMA; red), and Raptor (dark green) in the cross-section of small PA in
lung tissues from WT (Raptor-Oil) and RaptorSM/ (Raptor-Tam) mice (a). Summarized data (mean  SE; n ¼ 3 in each group) for DAPI, SMA, and Raptor fluo-
rescence intensity are shown in b. Student’s t-test, ***p < 0.001 versus Raptor-Oil. (C) Representative record of RVP (a) as well as summarized data (mean  SE)
showing the peak value of RVSP (b) (Kruskal-Wallis test, p < 0.001) and the Fulton index (RV/[LV þ S]) ratio (c) (Kruskal-Wallis test, p < 0.001) in WT (Oil-Creþ/
RaptorF/F) and RaptorSM/ (Tam-Creþ/RaptorF/F) mice exposed to normoxia (room air, 21% oxygen) and hypoxia (10% oxygen for 3 weeks). Dunn test, ***p < 0.001,
**p < 0.01 versus Normoxia-WT; #p < 0.05 versus Hypoxia WT. The numbers of experiments (n) for each group are indicated in each bar. Abbreviations as in Figure 1.
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proposed hypoxic experiments (for 3 weeks)
(Figure 1Ac). Immunohistochemistry experiments
were conducted to confirm that the expression of
Rictor was significantly down-regulated in PA cross-
sections from the lung tissues in RictorSM/ mice
compared with WT mice (Figures 3Ba and 3Bb).
In contrast to mTORSM/ and RaptorSM/ mice,
the RictorSM/ mice exhibited a slight, but not sta-
tistically significant, increase in RVSP and RVH
(determined by using the Fulton index) under nor-
moxic control conditions (Figures 3Ca and 3Cb)compared with WT mice. After 3 weeks of exposure to
normobaric hypoxia, RVSP and RVH were further
increased in both WT and RictorSM/ mice; however,
the hypoxia-induced increases in RVSP and RVH
(Figure 3Cc) were comparable between WT and
RictorSM/ mice. It was noted that the nonsignificant
difference in RVSP and the Fulton index between
hypoxic WT mice and hypoxic RictorSM/ mice was
somehow related to a slight, but not statistically sig-
nificant, increase in basal level of RVSP and RVH in
RictorSM/ mice (Figures 3Cb and 3Cc). These results
indicate the following: 1) that SM-specific deletion of
FIGURE 3 Rictor (mTORC2) in Smooth Muscle Cells and Pulmonary Hypertension
SM-specific conditional and inducible KO of Rictor increases basal RVSP and negligibly affects the development of hypoxia-induced pulmonary hypertension in
RictorSM/ mice. (A) Schematic strategy for the generation of RictorSM/ mice (a); Western blot analysis of Rictor (rapamycin insensitive companion of mammalian
target of rapamycin) in isolated PA from WT and RictorSM/ mice (b); and the timeline indicating the time for Tam injection (to induce Rictor KO), hypoxic exposure
(to induce PH) and experimental measurements (c). (B) Representative immunofluorescence images (a) and summarized data (mean  SE; n ¼ 5 in each group) (b)
showing cell nuclei (DAPI; blue), smooth muscle cells (SMA; red), and Rictor (dark green) in the cross-section of small PA in lung tissues from WT (Rictor-Oil) and
RictorSM/ (Rictor-Tam) mice. Student’s t-test, ***p < 0.001 versus Rictor-Oil. (C) Representative record of RVP (a) and summarized data (mean  SE) showing the
peak value of RVSP (b) (Kruskal-Wallis test, p < 0.001) and the Fulton index (RV/[LV þ S]) ratio (c) (Kruskal-Wallis test, p < 0.001) in WT and RictorSM/ mice
exposed to normoxia and hypoxia (for 3 weeks). Dunn test, *p < 0.05, ***p < 0.001 versus Normoxia-WT. (D) Representative hematoxylin and eosin images of the
cross-section of small PA (a) and summarized data (mean  SE) showing the PA wall thickness in WT and RictorSM/ mice under normoxic and hypoxic
conditions (b). (c) Hypoxia-induced increase in PA wall thickness in WT and RictorSM/ mice. The numbers of experiments (n) for each group are indicated in each
bar. Abbreviations as in Figure 1.
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751Rictor seems to, spontaneously, increase RVSP and
RVH under normoxic control conditions; and 2) that
SM-specific deletion of Rictor still inhibits hypoxia-
induced PH.
To examine whether the hemodynamic data are
consistent with the histological data, we also
measured and compared PA wall thickness in lung
tissues from WT and RictorSM–/– mice. The hypoxia-
induced increases in RVSP and RVH in WT mice
(Figure 3C) were associated with significant PA
remodeling, indicated by a significant increase in wall
thickness in small (<100 mm in diameter) arteries
(Figures 3Da and 3Db). Similar to WT mice, RictorSM–/–
mice also exhibited significant increases in PA wall
thickness after 3 weeks of hypoxic exposure
(Figure 3Dc); SM-specific deletion of Rictor failed to
inhibit hypoxia-induced PA thickening (Figure 3Dd)
during the development of HPH.
COMPARISON OF THE CHANGES IN RVSP AND THE
FULTON INDEX IN CONDITIONAL AND INDUCIBLE
mTOR-KO (mTORSML/L), Raptor-KO (RaptorSML/L),
and Rictor-KO (RaptorSML/L) mice. By comparing
the differences in RVSP and the Fulton index
under normoxic and hypoxic conditions between
mTORSM/, RaptorSM/, and RictorSM/ mice and
their WT mice, we found that there was a slight, but
not statistically significant, increase in both RVSP and
the Fulton index in RictorSM/ mice (w3 weeks after
injection of tamoxifen) under normoxic conditions
compared with the WT littermates; however, there
was no increase in RVSP or the Fulton index in
mTORSM/ and RaptorSM/ mice under normoxic
conditions. The mTORSM/ mice exhibited a 66%
inhibition of hypoxia-induced increase in RVSP (from
16.5  2.3 mm Hg in WT mice to 5.6  2.5 mm Hg in
mTORSM/ mice); the RaptorSM/ mice exhibited a
28% inhibition of hypoxia-induced increase in RVSP
(from 16.4  1.5 mm Hg in WT mice to 11.8  1.2
mm Hg in RaptorSM/ mice); and the RictorSM/
mice exhibited a 39% inhibition of hypoxia-induced
increase in RVSP (from 17.4  1.7 mm Hg in WT mice
to 10.6  2.4 mm Hg in RictorSM/ mice). Similar to
the data on RVSP, the mTORSM/ mice exhibited a
37% inhibition of hypoxia-induced increase in the
Fulton index (from 0.20  0.02 in WT mice to 0.12 
0.03 in mTORSM/ mice); the RaptorSM/ mice
exhibited a 36% inhibition of hypoxia-induced in-
crease in the Fulton index (from 0.12  0.12 in WT
mice to 0.08  0.01 in RaptorSM/ mice); and the
RictorSM/ mice exhibited a 27% inhibition of
hypoxia-induced increase in the Fulton index (from
0.21  0.03 in WT mice to 0.15  0.04 mm Hg in
RictorSM/ mice).RICTOR-KO (RictorSML/L) MICE EXHIBIT SPONTANEOUS
PH DUE TO PULMONARY VASCULAR REMODELING. To
further confirm that RictorSM/ mice may spontane-
ously develop PH under normoxic conditions, we
measured RVSP and the Fulton index in RictorSM/
mice at different times (3 or 6 months) after tamox-
ifen injection (Figure 4A) and then examined whether
intraperitoneal injection of imatinib, a tyrosine ki-
nase inhibitor that inhibits PDGFRs with high affinity,
had a reversal effect on established PH in RictorSM/
mice. As shown in Figure 4B, RictorSM/ mice
exhibited a significantly higher RVSP (Figures 4Ba and
4Bb) and Fulton index (Figure 4Bc) 3 months after
injection of tamoxifen under normoxic conditions
than the WT littermates. The increased RVSP and
Fulton index were maintained for up to 6 months
after tamoxifen injection (Figure 4Ba and 4Bb).
Furthermore, we also examined whether increased
RVSP in RictorSM/ mice was associated with signif-
icant pulmonary vascular remodeling. As shown in
Figure 4C, after 6 months of tamoxifen-induced Rictor
deletion, RictorSM/ mice displayed significantly
increased PA wall thickness (Figure 4Bc) compared
with the WT littermates. Inhibition of PDGFRs with
imatinib reversed PH (determined by increased RVSP)
and RV hypertrophy (determined by increased Fulton
Index) in RictorSM/ mice (Figure 4B).
These data indicate that SM-specific deletion of the
Rictor gene (RictorSM/) has a unique paradoxical
effect on the pulmonary vasculature or the pulmo-
nary circulatory system; the Rictor KO results in a
spontaneous increase in RVSP, likely due to pulmo-
nary vascular remodeling under normoxia. KO of
neither mTOR nor Raptor in smooth muscle cells or
PASMC has the spontaneous augmenting effect on
RVSP and PA wall thickening. The protective effect of
mTOR-KO is greater than the effect of Raptor-KO or
Rictor-KO, suggesting that both mTORC1 and
mTORC2 are involved in the development of HPH.
ENDOTHELIAL-SPECIFIC KO OF RICTOR FAILS TO
INDUCE SPONTANEOUS PULMONARY HYPERTENSION
IN RictorECL/L mice. To confirm that the pathogenic
role of Rictor KO or mTORC2 inhibition is specific to
smooth muscle cells, we created an EC-conditional
KO mouse strain by crossing floxed mice with Tie2-
CreER mice in which Cre expression is under the
control of Tie2 promoter (Figure 5A). Similar hemo-
dynamic and histological experiments were then
conducted in the EC-specific Rictor KO (RictorEC/)
mice. In contrast to the findings from the SM-specific
KO mice (RictorSM/), we found that neither the basal
RVSP (Figures 5Ba and 5Bb) and Fulton index
(Figure 5Bc) nor the hypoxia-induced increases in
FIGURE 4 Rictor Deletion in Smooth Muscle Cells Causes Spontaneous Pulmonary Hypertension
RictorSM/ mice spontaneously develop PH and imatinib reverses the established PH in RictorSM/ mice. (A) Schematic strategy for the
generation of RictorSM/ mice and the timeline indicating the time for Tam injection (to induce Rictor KO) and experimental measurements.
(B) Representative record of RVP (a) and summarized data (mean  SE) showing the peak value of RVSP (b) (Kruskal-Wallis test, p < 0.001)
and the Fulton index (RV/[LV þ S]) ratio (c) (Kruskal-Wallis test, p ¼ 0.001) in WT and RictorSM/ mice 3 and 6 months after Tam injection
with or without 2-week intraperitoneal injection of imatinib (20 mg/kg) daily. Dunn test, *p < 0.05, **p < 0.001, ***p < 0.001 versus WT;
#p < 0.05, ##p < 0.01 versus RictorSM/ (3 months). Summarized data of PA wall thickness in WT and RictorSM/ mice 6 months after Tam
injection (d). *p < 0.05 versus WT. The numbers of experiments or mice (n) for each group are indicated in each bar. Abbreviations as in
Figure 1.
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752RVSP and the Fulton index were changed in Ric-
torEC-/- mice compared with the WT littermates.
Furthermore, both WT and RictorEC/mice exhibited
significant increases in pulmonary vascular remodel-
ing, determined according to PA wall thickness, after
3 weeks of hypoxic exposure; no difference was
observed between WT mice and RictorEC/ mice
(Figures 5Ca and 5Cb). These data suggest thatendothelial-specific KO of Rictor has neither a pro-
tective effect on hypoxia-induced PH nor a patho-
genic effect on pulmonary vascular remodeling to
increase RVSP under normoxic conditions. The
spontaneous PH and consistent pulmonary vascular
remodeling in RictorSM/ mice are specific to Rictor/
mTORC2 inhibition in pulmonary vascular smooth
muscle cells.
FIGURE 5 Rictor Deletion in Endothelial Cells Fails to Cause Spontaneous Pulmonary Hypertension
Endothelial-specific conditional and inducible KO of Rictor fails to attenuates hypoxia-induced pulmonary hypertension in RictorEC/ mice.
(A) Schematic strategy for the generation of EC-specific Rictor-KO mice (RictorEC/) and the timeline indicating the time for Tam injection
and experimental measurements. (B) Representative record of RVP (a) and summarized data (mean  SE) showing the peak value of RVSP (b)
(Kruskal-Wallis test, p < 0.001) and the Fulton index (RV/[LV þ S]) ratio (c) (Kruskal-Wallis test, p < 0.001) in WT and RictorEC/ mice
exposed to normoxia and hypoxia (for 3 weeks). Dunn test, **p < 0.01, ***p < 0.001 versus Normoxia-WT. (C) Representative hematoxylin
and eosin images of the cross-section of small PA (a) and summarized data (mean  SE) showing the PA wall thickness in WT and RictorEC/
mice under normoxic and hypoxic conditions (b). The numbers of experiments or samples (n) for each group are indicated in each bar.
Abbreviations as in Figure 1.
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754ISOLATED PA OR PASMCs FROM RictorSM/ mice
exhibit up-regulation of PDGFRs (PDGFRa AND
PDGFRb). Increased PDGF and up-regulated PDGFRs
have been implicated in the development and pro-
gression of idiopathic and associated PAH and PH
associated with hypoxia and lung disease (35). To
examine whether deletion of Rictor increases RVSP
and the Fulton index due, at least partially, to up-
regulation of PDGFRs in PA or PASMCs, we isolated
PA from WT and RictorSM/ mice and compared
protein expression levels of PDGFRa and PDGFRb.
The expression level of PDGFRa and PDGFRb were
greater in PA isolated from RictorSM/ mice than in
PA isolated from WT mice (Figures 6Aa, b and 6Ba, b).
The KO of Rictor would lead to inhibition of mTORC2.
Indeed, pAKT (at S473 but not at T308), a major
downstream signaling protein of mTORC2, was
significantly decreased in the PA isolated from
RictorSM/ mice compared with the PA isolated from
WT mice (Figures 6A and 6B). The total AKT protein
expression level, however, did not differ in isolated
PA between WT and RictorSM/ mice (Figures 6Aa
and 6Ba). These data indicate that SM-specific dele-
tion of Rictor or inhibition of mTORC2 in RictorSM/
mice results in a spontaneous up-regulation of
PDGFRs (PDGFRa and PDGFRb) in PASMCs. It is un-
clear, however, whether the up-regulated PDGFRa/
PDGFRb were related to decreased pAKT (at S473) in
PA isolated from RictorSM/ mice.
We next examined and compared the expression
level of PDGFRa and PDGFRb in PA isolated from WT
and RictorSM/ mice under normoxic and hypoxic
conditions. Similar to the data shown in Figure 6A,
both PDGFRa and PDGFRb protein expression levels
were increased in PA isolated from RictorSM/ mice
compared with the PA from WT mice. In PA isolated
from WT mice with HPH, the protein expression level
of PDGFRa and PDGFRb was significantly greater than
in normoxic control WT mice. SM-specific KO of Ric-
tor in RictorSM/ mice caused a slight, but not sta-
tistically significant, up-regulation of PDGFRa and
PDGFRb in PA under hypoxic conditions compared
with their WT controls (Figure 6Bb, left and middle
panels). Furthermore, SM-specific KO of Rictor
significantly decreased pAKT at S473 in PA isolated
from mice exposed to normoxia and hypoxia; the
decreasing effect of Rictor KO on pAKT (S473) was
enhanced under hypoxic conditions (Figure 6Bb, right
panel). Quantitative analyses of the pulmonary arte-
rial PDGFRa and PDGFRb levels in WT and RictorSM/
mice indicate that the up-regulation of PDGFRa and
PDGFRb (Figure 6C) in PA associated with SM-specific
KO of Rictor under normoxic conditions is the same as
that under hypoxic conditions. Furthermore,hypoxia-induced increases in PDGFRa/PDGFRb pro-
tein expression in PA isolated from WT mice was not
different from that in PA isolated from RictorSM/
mice (Figure 6D). The decrease in pAKT (S473) due to
SM-specific KO of Rictor, however, was significantly
greater in hypoxia than in normoxia (Figure 6Bb, right
panel). These data imply that Rictor-KO and hypoxia
both up-regulate PDGFRa/PDGFRb in PA; the mecha-
nisms involved in hypoxia-induced PDGFRa/PDGFRb
up-regulation may be different from the mechanism
by which Rictor-KO (or mTORC2 inhibition) increases
PDGFRa/PDGFRb expression.
PHARMACOLOGICAL INHIBITION OF mTORC2
UP-REGULATES THE EXPRESSION OF PDGFRa AND
PDGFRb IN HUMAN PASMCs. Increased proliferation
of PASMCs and pulmonary arterial endothelial cells
(PAECs) has been implicated in the development and
progression of pulmonary vascular remodeling and
PH (36). Our reverse transcription polymerase chain
reaction experiments (Figure 7A) revealed the pres-
ence of messenger ribonucleic acid expression of
mTOR, Raptor, Rictor, Gbl, and Sin1 in human
PASMCs and PAECs, whereas Western blot experi-
ments (Figures 7Ba and 7Bb) indicated that PDGFRa
and PDGFRb were both expressed in human PASMCs
but not in human PAECs (or the expression level of
PDGFRa and PDGFRb in the PAECs was too low to be
detected). To further examine whether mTORC2 is
involved in up-regulating the expression of PDGFRa
and PDGFRb in vitro, PDGFRa and PDGFRb expres-
sion levels were compared in human PASMCs treated
with vehicle (Control), rapamycin (50 nM), or KU
0063794 (200 nM). Because we were unable to detect
PDGFRs in PAECs (Figure 7B), the focus of the in vitro
experiments was on PASMCs.
Short-term treatment (24 h) with rapamycin (50
nM), an mTOR1-specific inhibitor (although long-term
treatment with rapamycin has been reported to
inhibit mTOR2 as well) (37), had a negligible effect on
the protein expression levels of PDGFRa and PDGFRb
in PASMCs, increased pAKT (T308), and had no effect
on pAKT (S473) (Figures 7C and 7D). Treatment (24 h)
with KU 0063794, an inhibitor for both mTORC1 and
mTORC2, significantly up-regulated the protein
expression of PDGFRa and PDGFRb and increased
pAKT (T308) but decreased pAKT (S473). Both rapa-
mycin and KU 0063794 increased the activity of pAKT
(T308), but only KU 0063794 decreased the activity of
pAKT (S473). These in vitro experimental results
indicate that inhibition of mTORC2 can up-regulate
the expression of PDGFRa and PDGFRb in human
PASMCs, which is in agreement with our in vivo data
in mice showing that SM-specific KO of Rictor (which
FIGURE 6 Rictor (mTORC2) Contributes to Regulating PDGFR Expression in Smooth Muscle Cells
SM-specific conditional and inducible KO of Rictor up-regulates the protein expression of platelet-derived growth factor receptors (PDGFRs) in isolated PA. (A)Western
blot analyses on PDGFRa and PDGFRb, as well as phosphorylated AKT at S473 and T308, in PA isolated from WT and RictorSM/ mice (a). Summarized data (mean 
SE; n ¼ 3 in each group) showing PA expression levels of PDGFRa, PDGFRb, pAKT (S473), and pAKT (T308) in WT and RictorSM/ mice in PA isolated from WT and
RictorSM/mice (b). p values, determined by Student’s t-test are indicated in b, WT vs. RictorSM/mice. (B)Western blot analyses on PDGFRa, PDGFRb, pAKT (S473),
and AKT in PA isolated from normoxic and chronically hypoxic WT and RictorSM/ mice (a). Summarized data (mean  SE, n ¼ 3 in each group) showing PA
expression levels of PDGFRa, PDGFRb, and pAKT (S473) in WT and RictorSM/mice under normoxic and hypoxic conditions (b). Kruskal-Wallis test, p ¼ 0.02 and Dunn
test, *p < 0.05 versus Normoxia-WT or Normoxia-RictorSM/. (C) Summarized data (mean  SE; n ¼ 3 in each group) showing the changes (or differences) in
PA expression levels of PDGFRa (left panel) and PDGFRb (right panel) in RictorSM/ mice (compared with the WT controls) during normoxia and hypoxia.
(D) Summarized data (mean  SE; n ¼ 3 in each group) showing the hypoxia-induced changes in the protein expression level of PDGFRa and PDGFRb in WT mice
and RictorSM/ mice. The numbers of experiments (n) for each group are also indicated in each bar. Abbreviations as in Figure 1.
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755disrupts mTORC2) up-regulates PDGFRa and PDGFRb
in PA and contributes to spontaneous increases in
RVSP and the Fulton index in RictorSM/ mice under
normoxic control conditions.
Inhibition of mTORC2, either by SM-specific KO of
Rictor in vivo or pharmacological blockade with KU
0063974 in vitro, up-regulates PDGFRa/PDGFRb in
PASMCs. Therefore, treatment of PH with duel in-
hibitors of mTORC1 and mTORC2, such as rapamycin,
should be combined with a blocker of PDGFRs. To testthis hypothesis, we conducted in vivo experiments to
examine whether combination treatment with low
doses of rapamycin and imatinib (an inhibitor of
PDGFRs) would yield a better therapeutic effect on
experimental PH. As shown in Figure 7E, intraperito-
neal injection of a low dose of rapamycin (5 mg/kg)
resulted in a 29% inhibition of hypoxia/Sugen–medi-
ated increase in RVSP (Figures 7Ea and 7Eb) and
RVH (determined by the ratio of RV/[LV þ S] and the
ratio of right ventricle weight to body weight)
FIGURE 7 mTORC2 Regulates PDGFR Expression in Smooth Muscle Cells
Pharmacological inhibition of mammalian target of rapamycin complex 2 (mTORC2) up-regulates the protein expression of PDGFRa and PDGFRb in pulmonary arterial
smooth muscle cells (PASMCs). Reverse transcription polymerase chain reaction analyses on (A) mTOR, Raptor, Rictor, GbL, and Sin1 as well as (B) PDGFRa and
PDGFRb (a) in human PASMCs and pulmonary arterial endothelial cells (PAECs). Summarized data (mean  SE) (b) showing the levels of PDGFRa and PDGFRb in human
PASMCs (n ¼ 6) and PAECs (n ¼ 6). Welch’s t-test, ***p < 0.001 vs PASMC. (C) Western blot analyses on PDGFRa and PDGFRb in human PASMCs and PAECs treated
with vehicle (Cont), 50-nM rapamycin (Rap), and 200-nM KU 0063794 (KU) for 24 h. (D)Western blot analyses on PDGFRa, PDGFRb, pAKT (T308), pAKT (S473), and
AKT in PASMCs treated with vehicle (Cont), Rap, and KU (for 24 h) (a). Summarized data (mean  SE) showing the levels of PDGFRa (Kruskal-Wallis test, p < 0.001;
n ¼ 9), PDGFRb (Kruskal-Wallis test, p ¼ 0.01; n ¼ 7), pAKT (T308) (Kruskal-Wallis test, p < 0.001; n ¼ 9), and pAKT (S473) (Kruskal-Wallis test, p < 0.001; n ¼ 7) in
control PASMC and PASMC-treated Rap and KU (b). Dunn test, *p < 0.05, **p < 0.01 versus Control. (E) Representative record of RVP in control rats and hypoxia/
Sugen (Hyp/Su) rats treated with vehicle, Rap (5 mg/kg body weight, intraperitoneally), imatinib (Imat, 20 mg/kg body weight, intraperitoneally), or combination of
Rap and Imat (Rap/Imat) (a). Summarized data (mean  SE) (b–d) in control rats (Cont) and Hyp/Su rats treated with vehicle (V), Rap (R), Imat (I), or Rap and Imat
(R þ I) showing peak RVSP (b) (Kruskal-Wallis test, p < 0.001), the Fulton index (c) (Kruskal-Wallis test, p < 0.001), and the ratio of right ventricle weight to body
weight (RV/BW) (d) (Kruskal-Wallis test, p < 0.001). Dunn test, *p < 0.05, **p < 0.01, ***p < 0.001 versus Control; Student’s t-test, #p < 0.05, ##p < 0.01,
###p<0.001 versus Hyp/Su with Vehicle (V) and Hyp/Su with Imatinib (I). Abbreviations as in Figures 1 and 6.
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756(Figures 7Ec and 7Ed). The low dose of imatinib (20
mg/kg) had no effect on RVSP (Figures 7Ea and 7Eb)
but slightly (with statistical significance) inhibited
hypoxia/Sugen –mediated increases in the Fulton
index (Figure 7Ec) and the ratio of right ventricular
weight to body weight (Figure 7Ed). However, com-
bination of the low doses of rapamycin and imatinib
resulted in w60% inhibition of the hypoxia/Sugen–
mediated increase in RVSP (Figures 7Ea and 7Eb).
These data suggest that blockade of PDGFRs usingtyrosine kinase receptor antagonists (e.g., imatinib)
could enhance the therapeutic effect of mTORC1/
mTORC2 inhibitors.
The low dose of rapamycin alone, however, resulted
in a 58.3% inhibition of the hypoxia/Sugen–induced
increase in the Fulton index, while combination
treatment of rapamycin and imatinib did not further
inhibit the hypoxia/Sugen–mediated increase in the
Fulton index (by 57.9%) (Figure 7Ec). Further study is
needed to investigate the potential difference of the
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757effect of rapamycin and imatinib on pulmonary
vascular smooth muscle cells and cardiomyocytes.
PHARMACOLOGICAL INHIBITION OF mTORC2
INCREASES THE NUCLEAR FORKHEAD BOX O3
LEVEL IN PASMCs. Forkhead box O3a (FOXO3a) is a
transcription factor that promotes cell apoptosis and
induces cell cycle arrest (38). FOXO3a is inhibited by
AKT or by pAKT-mediated phosphorylation at T32,
S253, and S315; more specifically, nuclear trans-
location of FOXO3a is inhibited by pAKT-mediated
phosphorylation at T32, S253, and S315. Therefore,
pAKT-associated phosphorylation of FOXO3a, due to
aberrantly activated mTOC2/AKT (39,40), leads to
transcriptional inhibition of target genes such as the
PDGFRs (41,42). We found that treatment (24 h) of
human PASMCs with rapamycin or KU 0063794
increased the level of total FOXO3a (or FOXO3a in the
total protein of the PASMCs). Interestingly, the
nucleocytoplasmic separation experiments showed
that rapamycin seemed to have a slight, but not sta-
tistically significant, increasing effect on the protein
level of cytoplasmic FOXO3a, whereas KU 0063794
mainly increased protein level of nuclear FOXO3a
(Figure 8A). Furthermore, the immunohistochemistry
experiments produced similar results. Both rapamy-
cin and KU 0063794 increased the protein expression
level of FOXO3a in human PASMCs (Figure 8B). The
fluorescence intensity of FOXO3a (green) was mainly
increased in the cytoplasm after rapamycin treat-
ment, whereas the fluorescence intensity of FOXO3a
(green) was mainly increased in the nuclei after KU
0063794 treatment (Figure 8Ba). The line-scan and
bar graphs (Figures 8Bb and 8Bc) all show that KU
0063794 significantly decreased pAKT at S473
(Figure 7D) and increased the nuclear FOXO3a
(Figures 8Bb and 8Bc), whereas rapamycin did not
significantly decrease pAKT at S473 (Figure 7D) and
actually decreased the nuclear FOXO3a (Figure 8Bc).
Taken together, these data indicate that inhibition of
mTORC2 increases the activity of FOXO3a in PASMCs,
which may be the mechanism in which PDGFR is
negatively regulated by mTORC2.
DISCUSSION
Increased PVR is a major contributor to the elevated
pulmonary arterial pressure in patients with idio-
pathic PAH (43). Sustained pulmonary vasoconstric-
tion (due to PASMC contraction) and concentric
pulmonary vascular wall thickening (due partially to
PASMC proliferation and migration) are 2 major cau-
ses of elevated PVR (and pulmonary arterial pressure)
in patients with idiopathic and associated PAH and in
animals with experimental PH (2,3). The PI3K/AKT/mTOR signaling pathway, as one of the key signaling
cascades to stimulate cell proliferation and survival,
plays an important pathogenic role in the develop-
ment and progression of PH (20,44). Many G protein-
coupled receptors (GPCRs), such as endothelin re-
ceptor A and Ca2þ-sensing receptors, and tyrosine
kinase receptors (TKRs), such as PDGFRs, are highly
expressed in PA and PASMCs from patients with PAH
(35,45,46). Activation of the up-regulated GPCR (e.g.,
endothelin receptor A and Ca2þ-sensing receptors)
and TKR (e.g., PDGFRa and PDGFRb) by mitogenic
factors and cytokines is one of the important mech-
anisms leading to abnormal cell growth, proliferation,
and migration. Increased extracellular ligands (e.g.,
endothelin-1, spermine, PDGF) and up-regulated
expression of various GPCRs (e.g., endothelin recep-
tor A, Ca2þ-sensing receptors) and TKRs (PDGFR)
have been implicated in the development and pro-
gression of pulmonary vascular remodeling in pa-
tients with PAH (35,46,47). Pharmacological blockade
or small interfering ribonucleic acid–mediated down-
regulation of various GPCRs and TKRs in PASMCs,
PAECs, and fibroblasts inhibits mitogen-mediated cell
proliferation and attenuates the development and
progression of PAH in patients and experimental PH
in animals (48–50).
The present study found the following: 1) SM-
specific KO of mTOR (mTORSM/), which disrupts
the function of both mTORC1 and mTORC2, signifi-
cantly attenuates the development of hypoxia-
induced PH (resulting in a 66% inhibition of
hypoxia-induced increase in RVSP), but has a negli-
gible effect on RVSP and the Fulton index under
normoxic control conditions; 2) SM-specific KO of
Raptor (RaptorSM/), which disrupts the function of
mTORC1, also significantly attenuates the develop-
ment of hypoxia-induced PH (resulting in a 28% in-
hibition of hypoxia-induced increases in RVSP) but
has a negligible effect on RVSP and the Fulton index
under normoxic control conditions; 3) SM-specific KO
of Rictor (RictorSM/), which disrupts the function of
mTORC2, attenuates the development of hypoxia-
induced PH (resulting in a 39% inhibition of
hypoxia-induced increases in RVSP) but has little ef-
fect on hypoxia-induced PA wall thickening; 4)
RictorSM/mice spontaneously develop mild PH, and
RVSP and the Fulton index were increased, respec-
tively, from 22.1  0.14 mm Hg and 0.22  0.02 to 30.5
 1.6 mm Hg (38.0% increase; p < 0.01) and 0.31 
0.06 (40.9% increase; p < 0.01) 3 months after
tamoxifen injection and to 31.3  1.3 mm Hg (41.2%
increase; p < 0.001) and 0.31  0.04 (40.9% increase;
p < 0.001) 6 months after tamoxifen injection; and 5)
the spontaneous increase in RVSP and the Fulton
FIGURE 8 mTORC2 Regulates PDGFR Expression via FOXO3a in Smooth Muscle Cells
Pharmacological inhibition of mTORC2 up-regulates the nuclear protein expression of Forkhead box O3a (FOXO3a) in human PASMCs. (A) Representative images
showing Western blot analyses on FOXO3a in the total, nuclear, and cytoplasmic proteins idolated from human PASMCs treated (for 24 h) with vehicle (Cont), Rap
(50 nM), and KU 0063794 (KU, 200 nM) (a). Summarized data (mean  SE) showing the total (Kruskal-Wallis test, p ¼ 0.01; n ¼ 4 in each group), nuclear (Kruskal-
Wallis test, p ¼ 0.01; n ¼ 5 in each group), and cytoplasmic (Kruskal-Wallis test, p ¼ 0.06; n ¼ 5 in each group) protein levels of FOXO3a in PASMCs treated with
vehicle (Control; blue bars), Rap (green bars), and KU (red bars) (b). Dunn test, *p < 0.05, **p < 0.01 versus Control; #p < 0.05 versus rapamycin. (B) Repre-
sentative immunofluorescence images showing cell nuclei (DAPI; blue) and FOXO3a (dark green) in human PASMCs treated (for 24 h) with vehicle (Control), Rap
(50 nM), and KU (200 nM) (a). The fluorescence intensity of FOXO3a along the line across a PASMC (b) treated with vehicle (Control), Rap, and KU. Summarized data
(mean  SE) showing the mean fluorescence intensity of the nuclear FOXO3a (c) in Control (n ¼ 24), Rap-treated (n ¼ 18), and KU-treated (n ¼ 21) PASMCs; the value
was calculated as the ratio of the nuclear intensity of FOXO3a to the cytoplasmic fluorescence intensity of FOXO3a. Kruskal-Wallis test, p < 0.001 and Dunn test,
***p < 0.001 versus Control; ###p < 0.001 versus rapamycin. Abbreviations as in Figures 1 and 7.
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758index in RictorSM/ mice is associated with an up-
regulation of PDGFRa and PDGFRb in PA, and intra-
peritoneal injection of the PDGFR inhibitor imatinib
reversed the established PH in RictorSM/ mice.These data indicate that the PI3K/AKT/mTOR
signaling pathway plays an important pathogenic
role in the development of PH. SM-specific KO of
Rictor or dysfunction of mTORC2 has a paradoxical
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759effect on the pulmonary vasculature, which attenu-
ates experimental PH (or hypoxia-induced PH) via its
inhibitory effect on AKT/mTORC1 signaling (mTORC2
is upstream of mTORC1 and positively regulates
mTORC1 activity) and results in up-regulation of
PDGFRa and PDGFRb via phosphorylating AKT at
S473 that contributes to a basal increase in RVSP and
RVH.
Our previous studies indicated that phosphoryla-
tion of AKT in lung tissues and PASMCs was increased
in patients with idiopathic PAH and in animals with
experimental PH compared with controls; up-
regulation of PTEN in PTEN transgenic mice attenu-
ated experimental PH (implying a critical role for PI3K
in the development of PH); global KO of the Akt1 gene
(Akt1/) inhibited the development of experimental
PH and RVH, whereas global KO of the Akt2 gene
(Akt2/) had a negligible protective effect on
hypoxia-induced PH and RVH (16); and genetic dele-
tion of the mTOR gene (mTOR/) exerted a signifi-
cant protective effect on hypoxia-induced PH and
RVH in HPH mice. These observations implied that
the PI3K/AKT1/mTOR signaling in PASMCs is required
or significantly involved in the development of
experimental PH.
The structural and functional complexities of
mTORC1 and mTORC2, as well as their multiple
protein interacting surfaces and regulatory role in
PASMC proliferation and survival, make it difficult
to rationalize which protein subunit should be
considered to study in detail to define the potential
differential effect of mTORC1 and mTORC2 on the
development of PH (17,51,52). We have focused our
experiments on the conserved proteins that have
equivalent function in both complexes (mTORC1
and mTORC2) and are conserved in patients with
PAH and in rodent PH models. Thus, we chose to
investigate the pathogenic role of Raptor, a major
protein subunit in the mTORC1 complex, and Rictor,
a major protein subunit in the mTORC2 complex
(53), in this study. There are multiple agonists that
are identified to activate mTORC1 and mTORC2 by
activating GPCR/TKR and eventually lead to cell
proliferation and survival (54). Although the list of
interacting proteins associated with mTORC1 and
mTORC2 is growing, it is important to understand
the individual upstream and downstream regulators
of mTORC1 and mTORC2 in their potential patho-
genic roles in the development of PH.
Both mTORC1 and mTORC2 are activated to
induce angiogenesis and cell proliferation in
response to hypoxia (44,55,56). Furthermore, studies
have shown that mTORC1 has an early activatingeffect and late inhibitory effect on angiogenesis and
cell proliferation in response to hypoxia, whereas
mTORC2 only has a delayed and maintained acti-
vating effect on cell proliferation in response to
hypoxia (44). In addition to cell proliferation and
growth, mTORC1 is also involved in regulating pro-
tein synthesis, ribosome biogenesis, transcriptional
control, and autophagy (57), whereas mTORC2 reg-
ulates the organization of the actin cytoskeleton and
determines the motility and shape of the cell
through Rho-type GTPases and protein kinase C (33).
The upstream regulators of the mTORC1 pathway
include various intracellular signals that are acti-
vated by growth factors, stress, energy metabolism,
hypoxia and hyperoxia, and amino acids (58). The
heterodimer TSC2 is a key upstream regulator of
mTORC1 and functions as a GTPase-activating pro-
tein for Rheb (Ras homolog enriched in brain) (59).
Loss of TSC2 increases cell proliferation and sur-
vival, and this effect also requires mTORC2 and its
downstream effector Rho GTPase (20). Rapamycin
inhibits the interaction of Raptor with other subunits
in the mTORC1 complex, whereas Rictor, conversely,
forms a rapamycin-insensitive complex with other
components in mTORC2 (29). These findings suggest
cooperative mechanisms between the signals from
mTORC1 and mTORC2, and it becomes essential to
understand the differential role played by mTORC1
and mTORC2 in stimulating cell proliferation and
survival.
Many studies indicate that mTORC1 and mTORC2
function differently in regulating gene expression,
cell proliferation, and growth (44). KO of mTOR
would disrupt the function of both mTORC1 and
mTORC2 (60). The goal of the present study was to
examine the potential divergent or differential role of
mTORC1 and mTORC2 in the development of PH. To
achieve this goal, the protective effects of the
following were compared: 1) the SM-specific and
tamoxifen-inducible Raptor KO on pulmonary he-
modynamic variables in RaptorSM/ mice in which
the mTORC1 function is disrupted in PASMCs; and 2)
the SM-specific and tamoxifen-inducible Rictor KO on
RVSP and the Fulton index in RictorSM/ mice in
which the mTORC2 function is disrupted in PASMCs.
In consistent with our previously published data
using mTOR/ mice (16), we found that SM-specific
and tamoxifen-inducible KO of mTOR resulted in a
66% inhibition of HPH or hypoxia-induced increase
in RVSP in mTORSM/mice. SM-specific KO of Raptor
or induced inhibition of mTORC1 in PASMC
(RaptorSM/) caused a 28% inhibition of hypoxia-
induced increase in RVSP or HPH. Neither mTORSM/
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Idiopathic PAH is a fatal and progressive disease
characterized by increased PVR creating strain on the
right ventricle that can progress to right heart failure
and death. Current therapies remain insufficient with
the absence of effective disease-modifying or pre-
ventive interventions, and application of most of the
current agents is hampered by undesirable side ef-
fects. Our study is the first to report a promising
therapeutic strategy of combination treatment with
an inhibitor of PDGFR and an inhibitor of mTOR on
PAH. We show that inhibition of mTORC1 ameliorates
experimental PH, whereas inhibition of mTORC2 up-
regulates PDGFR in PASMCs and compromises the
therapeutic effect of mTOR inhibition on PH.
Furthermore, we show that intraperitoneal injection
of imatinib completely reverses the established PH in
Rictor-KO mice, whereas the combination therapy
with rapamycin and a low dose of imatinib dramati-
cally reverses the established severe PH in rats (hyp-
oxia/Sugen–induced PH); rapamycin alone only caused
25.7% inhibition.
TRANSLATIONAL OUTLOOK: The data from these
in vitro and in vivo animal studies, although with
limitations, strongly suggest a combination thera-
peutic strategy using inhibitors of mTOR and PDGFRs
for PAH and PH associated with hypoxia and lung
diseases.
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760mice nor RaptorSM/ mice exhibited spontaneous PH
or RVH under normoxic conditions. SM-specific KO of
Rictor or induced inhibition of mTORC2 in PASMC
(RictorSM/) resulted in a 39% inhibition of HPH or
hypoxia-induced RVSP increase in RVSP, but caused
spontaneous PH or a 38% to 42% increase in RVSP
under normoxic control conditions. The increase of
the basal RVSP in RictorSM/ mice was associated
with an increased protein expression of PDGFRs
(PDGFRa and PDGFRb) in PA and PASMCs, and inhi-
bition of PDGFR with imatinib reversed the estab-
lished PH in RictorSM/ mice.
The protein expression level of both PDGFRa and
PDGFRb in PASMCs isolated from patients with
idiopathic PAH were greater than in PASMCs isolated
from normal subjects. Furthermore, chronic hypoxia
also up-regulated PDGFRa and PDGFRb in PA and
PASMCs isolated from animals. These data indicate
that up-regulation of PDGFRs in PASMCs is also
involved in the development of PAH/PH, due
potentially to enhanced PASMC proliferation via a
PDGF/PDGFR/PI3K/AKT/mTOR signaling pathway.
The pathogenic effect of SM-specific Rictor-KO due
to PDGFR up-regulation and the protective effect of
SM-specific Rictor-KO due to mTORC2/AKT inhibi-
tion on experimental PH indicate that Rictor or
mTORC2 has a paradoxical effect on the pulmonary
vascular structure and function. The paradoxical
effect of SM-specific KO of Rictor or inhibition of
mTORC2 is also an important finding implying that
combination use of inhibitors of mTORC2/AKT (and
AKT/mTORC1) and inhibitors of PDGFRs would have
a more efficient therapeutic or protective effect on
PAH/PH.
CONCLUSIONS
The PI3K/AKT1/mTORC1 signaling pathway is an
important signaling cascade associated with GPCR/
TKR–mediated PASMC proliferation and growth. The
receptor-mediated AKT1 phosphorylation and the
increase in mTORC1 kinase activity are critical in
transferring the extracellular proliferative or mito-
genic signals to the nucleus of PASMCs. Activation
of the PI3K/AKT1/mTORC1 signaling cascade plays
an important pathogenic role in the development of
pulmonary vascular remodeling and PH. Down-
regulation or inhibition of mTOR (required for the
function of mTORC1 and mTORC2), Raptor (required
for the function of mTORC1), and Rictor (required
for the function of mTORC2) ameliorate the experi-
mental PH in mice. In addition to inhibitinghypoxia-induced PH, however, down-regulation of
Rictor or inhibition of mTORC2 also up-regulates
PDGF receptors in PASMCs, whereas RictorSM/
mice exhibit spontaneous PH that can be reversed
by inhibition of PDGFRs (with imatinib). Because the
inhibition of mTORC2 results in a paradoxical effect
of experimental PH, we suggest that therapeutic
regimens using inhibitors of the PI3K/AKT/mTOR
signaling cascade for the treatment of PH and PAH
should include an inhibitor of PDGFR (e.g., imatinib)
due to the up-regulation of PDGFRa and PDGFRb
induced by mTORC2 inhibition.
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